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ABSTRACT  
Some forms of bovine lactoferrin (bLf) are effective in delaying Clostridioides difficile growth 
and preventing toxin production. However, therapeutic use of bLf may be limited by protein 
stability issues. The objective of this study was to prepare and evaluate colon-targeted, pH-
triggered alginate microparticles loaded with bioactive bLf and to evaluate their anti-C. 
difficile defence properties in vitro. Different forms of metal-bound bLf were encapsulated in 
alginate microparticles using an emulsification/internal gelation method.  The microparticles 
were coated with chitosan to control protein release. In vitro drug release studies were 
conducted in pH-simulated gastrointestinal conditions to investigate the release kinetics of 
encapsulated protein. No significant release of metal-bound bLf was observed at acidic pH; 
however, on reaching simulated colonic pH, most of the encapsulated lactoferrin was 
released. The application of bLf (5mg/mL) delivered from alginate microparticles to human 
intestinal epithelial cells (hIECs) significantly reduced the cytotoxic effects of toxins A and B 
as well as bacterial supernatant on Caco-2 and Vero cells, respectively. These results are 
the first to suggest that alginate-bLf microparticles show protective effects against C. difficile 
toxin-mediated epithelial damage and impairment of barrier function in hIECs. The future 
potential of lactoferrin-loaded alginate microparticles against C. difficile deserves further 
study. 
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1. Introduction 
Successful oral delivery of peptides and proteins requires protection of the macromolecules 
from loss of bioactivity or degradation in the gastrointestinal tract.1,2 Targeted delivery of 
drugs and proteins into the colon is important for local treatment of a range of diseases.3 
Different approaches have been developed for colon specific drug delivery including coating 
with pH- responsive polymers, preparing timed-release formula, and colonic bacteria 
responsive degradation of formula.4,5 Among the aforementioned strategies, the use of pH-
responsive polymers holds great promise. Various pH-triggered polymer polysaccharides 
have been studied for this purpose.6 
Alginate microparticles possess some unique characteristics that enable these particles to 
be used for the controlled delivery of proteins. For example, alginate microparticles have 
excellent biodegradability, biocompatibility, and pH-responsive swelling behaviour. As a 
consequence, alginates are used in a number of pharmaceutical applications, but alginate 
particles in particular are used to control release of oral delivery of drugs and 
proteins.7,8,9,10,11,12,13 Alginate-derived polymers can easily be formulated into controllable 
diameter microparticles with appropriate size distributions for ingestion (~100 µm).7 These 
particles can be prepared by various techniques such as microfluidic fabrication,14,15,16,17 air 
atomization,18,19,20 emulsification/internal gelation,21 complexation with counterion polymers,22 
spray-drying,23 impinging aerosols,24,25 and inkjet/drying processes.26 Among these 
techniques, emulsification/internal gelation methods have particular advantages for 
encapsulation of bioactive proteins due to the mild preparation conditions and potential for 
scale-up. However, a limitation of conventionally-prepared calcium-crosslinked alginate 
microparticles is the openness of their internal structure which can result in burst drug 
release profiles. Thus, alginate microparticles are mainly coated with other polycationic 
polymers to improve their mechanical integrity in the gastrointestinal fluids.27,28,29,30,31 Moreover, 
other studies have found that combination of alginate and other polymers during the gelation 
process is a promising strategy for gastro-protective delivery of bioactive molecules.13,32,33 In 
particular, chitosan-coated alginate microspheres are effective in protecting probiotic bacteria 
from gastric acid and bile salts. 34  
In a recent study, we reported that some forms of bovine lactoferrin (bLf) are effective in 
substantially delaying Clostridioides difficile growth and preventing production of toxins in a 
human in vitro gut model of C. difficile infection (CDI).35 Specifically, iron-saturated, but not 
iron-depleted bLf at a concentration of 5 mg/mL exerted this inhibitory effect. In separate 
batch culture experiments, iron-saturated bLf prevented C. difficile vegetative cell growth and 
toxin production, whereas iron-depleted-bLf and iron alone did not.35 Furthermore, in 
comparison to iron-depleted bLf, iron- saturated bLf was observed to be more resistant to 
proteolytic degradation. It is well known that the therapeutic use of bLf may be limited by 
protein stability issues. For example, it has been reported that the absolute oral 
bioavailability levels of native Lf may be less than 1%, limited mainly by enzymatic 
degradation in the gastrointestinal tract and by its poor absorption across intestinal 
epithelium. 36 Thus, the objective of this study was to prepare and evaluate colon targeted 
and pH-triggered alginate microparticles loaded with bioactive lactoferrin and to evaluate 
subsequently their anti-C. difficile defence properties in vitro. Previous work has reported a 
non-toxic profile for various forms of bLf irrespective of their metal saturation status. 37  In this 
study, different forms of lactoferrin (iron-depleted; apo-bLf, iron-saturated; Fe-bLf, and 
manganese-saturated; Mn-bLf) were encapsulated in chitosan-coated alginate microparticles 
fabricated under mild conditions using the emulsification/internal gelation method.  
 
 
2. Materials and Methods 
2.1. Materials 
Sodium alginate (Fisher Scientific UK, catalogue number 1046-8800, general laboratory 
grade, molar masses not defined), bovine serum albumin–fluorescein isothiocyanate 
conjugate (BSA-FITC), high molecular weight chitosan (>75% degree of deacetylation, 
molecular weight 310-375 kD) were obtained from Sigma-Aldrich UK. iron-saturated (85% 
Fe3+ saturated) bovine holo-lactoferrin (holo-bLf), iron-depleted (1% Fe3+ saturated) bovine 
apo-lactoferrin (apo-bLf), and manganese saturated bovine lactoferrin (Mn-bLf) were 
prepared according to the published procedure. 37-38 Highly purified C. difficile whole toxins A 
and B toxinotype 0, strain VPI 10463, ribotype 087, were supplied by Public Health England. 
All other analytical grade reagents were used without additional purification. Deionized 
distilled water was used to make all solutions. Calcium chloride dihydrate (CaCl2H2O) was 
purchased from Sigma-Aldrich UK and used as supplied. Dulbecco’s modified eagle media 
(DMEM), 1% ι-glutamine (2 mM), 1% antibiotic/antimycotic solution, 10% fetal calf serum 
(FCS), and 1 % non-essential amino acids were obtained from Sigma Aldrich (UK). The MTT 
cell metabolic activity reagent was purchased from Invitrogen. Trypan blue solution was 
obtained from Sigma Aldrich (UK). 
2.2. Synthesis of bLf-loaded alginate microparticles  
The emulsification/internal gelation method was used to prepare the protein-loaded alginate 
microparticles (Figure 1). A solution of sodium alginate (2% w/v) was first prepared in 
deionized water and after this, a suspension of 5% (w/v) of ultrafine CaCO3 was added into 
the alginate solution. Then, a previously prepared lactoferrin solution in deionised water (1% 
w/v) solution was added to the above mixture and the resultant mixture was homogenised, 
before being dispersed into a mixture of paraffin oil and surfactant (Span 80 1% v/v) and 
stirred at 1000 rpm for 15 min using an IKA-Eurostar digital mixer with a Turbine stirrer. 
Following this step, a mixture of paraffin oil and glacial acetic acid (20 mL) was added to the 
above water-in-oil emulsion to reduce the pH of the mixture to ~ 5. Continuous stirring 
resulted in the production of microparticles, which were recovered from the oil phase by 
using a mixture of Tween 80 (1% v/v): CaCl2 (0.05 M), distilled water, and acetate buffer at 
pH 5.5 as washing media. The microparticles were further rinsed until optical microscopy 
indicated that no more oil was associated with the separated particles.  
2.3. Synthesis of chitosan-coated alginate microparticles  
A chitosan solution (0.1% w/v) was prepared by dissolving chitosan (0.1g of a 310-375 kD 
molar mass range) in 100 mL of acetic acid (1% v/v) with continuous stirring for 30 minutes. 
Next, the pre-prepared alginate microparticles were added to the chitosan solution. The 
newly formed and surface-coated microparticles were transferred into a CaCl2 solution 
(0.5%) and washed with deionized water repeatedly. The resultant microparticles were 
stored until further use.  
2.4. Preparation of Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid 
(SIF)  
A solution of SGF was prepared by dissolving sodium chloride (2g) in 1000 mL of water 
acidified with HCl to a pH of 1.2. Simulated Intestinal Fluid Test Solution was synthesised by 
dissolving monobasic potassium phosphate (6.8g) in water (250mL), then adding sodium 
hydroxide (0.2M, 77mL) and water (500mL). The pH of this solution was adjusted to 7.4 prior 
to use. 
2.5. Determination of protein encapsulation efficiency of the microparticles  
Protein-loaded microparticles (10 mg) were dispersed in PBS at pH of 7.4 (100 mL, 
containing 5% (v/v) ethanol) and stirred continuously for 24 h. UV-Vis spectrophotometry 
was used to determine the amount of free protein in supernatant via absorption at 450 nm. 
The protein content and loading efficiency was calculated as described by Bosio et al 201412 
from experimentally determined calibration curves of protein content with UV absorption. 
2.6. In vitro release studies 
Simulated gastrointestinal conditions without enzyme (SGF pH 1.2 and SIF pH 7.4) were 
used to investigate in vitro release of encapsulated protein. Protein-loaded microparticles 
(10 mg) were added to SGF (pH 1.2, 10 mL) and stirred at 100 rpm for 2 h. Then, the 
mixture was centrifuged and separated microspheres were added into SIF (pH 7.4, 10 mL) 
and stirred for another 2 h. Samples were taken at different time intervals from both FGF and 
SIF solutions to determine the protein concentration spectrophotometrically. All assays were 
performed in triplicate. Protein release was calculated according to the following equation. 
Protein release % = Mt / Mt0 * 100 
Where Mt is the amount of protein at time t and Mt0 is the amount of protein in the 
microparticles at time t = 0.  
2.7. Growth of C. difficile in vitro and preparation of bacterial supernatants  
We used C. difficile strain 027 (PCR Ribotype 027/toxinotype III) in this study. This strain 
was prepared at Maine Medical Center (Portland, ME, USA) and was kindly supplied by Dr 
Daniela Heeg, CHAIN Biotechnology. Spores were first grown on egg yolk 
agar/cycloserine/cefoxitin with lysozyme (CCEY/L) for 48 h, then transferred to a Columbia 
Blood agar plates. To prepare bacterial supernatants, the cultures of C. difficile were 
centrifuged at 10,000 g for 10 min and then filtered using 0.22-µm filter to remove bacterial 
cells. Both cultures and supernatants were stored at 4°C. 
2.8. Cultivation of Vero and Caco-2 cells on culture flasks  
Both Vero and Caco-2 cells were maintained in DMEM culture media, in a humidified 
atmosphere at 37oC and 5% CO2. The medium was changed every 48 h. When the cells 
reached 70-80% of their confluence, they were split using trypsin to detach cells. 
2.9. Cultivation of Caco-2 cells on transwell plates  
Caco-2 cells were maintained in complete DMEM cell culture media. The media was 
supplemented with 2 mM L-glutamine, 0.1% penicillin-streptomycin solution, 10% fetal 
bovine serum, and 1% non-essential amino acid solution in a humidified atmosphere at 37oC 
and 5% CO2. The cells were allowed to grow under the standard conditions until they 
reached 60–70% of their confluency. Cells from passages 60-80 were used in all 
experiments. The cells were seeded on permeable supports (Transwell, Corning, 1.12 cm2 
area, 12 mm diameter, and 0.4 μ m pore size), and the seeding density was 2×104 cells/cm2. 
The culture medium was added to the upper and lower compartments of the wells and the 
medium was changed every 48 h.  
 
2.10. Measurement of the Transepithelial Electrical Resistance (TEER)  
Barrier function integrity of the Caco-2 cell monolayers was assessed by measurement of 
TEER, using a portable epithelial Voltohmmeter (EVOM2, World Precision Instruments). 
Caco-2 cells were grown in the upper compartment of transwell inserts at 37°C, 5% CO2. 
Cells were used for TEER measurements between days 14 and 21 post seeding. At the end 
of the growth period, plates were equilibrated at room temperature for 1 h. TEER 
measurement was conducted to evaluate possible damage to cell integrity of monolayer 
cultured cells during the experiments. The TEER values were determined from the potential 
difference between the upper compartment and lower compartment, connected to a pair of 
‘chopstick’ electrodes. The cells were washed twice with phosphate buffered saline (PBS) 
and pre-equilibrated for 1 h with Hanks’ balanced salt solution (HBSS) before performing 
TEER measurements. Thereafter, the media was removed and 200 μL of materials (toxins A 
or B, or/and final chitosan-coated alginate microparticles loaded with 5 mg/mL of bLf) were 
added to the upper (apical) compartments of the transwell inserts. Subsequently, TEER 
measurements were conducted at 4 h, 24 h and 48 h and recorded as electrical resistance 
at time 0. The electrical resistance for blank insert (no cells) and for each well was recorded.  
2.11. Trypan Blue Exclusion Assay  
Cells were incubated with trypan blue in a humidified atmosphere at 37oC and 5% CO2 at a 
final concentration of 0.01% and visualised under light microscopy for determination of the 
numbers of viable (unlabeled) and damaged (blue) cells. Viability was denoted as the ratio of 
live cells per total cell number. After culture for 1 h, at least 200 blue cells per well were 
counted to determine the proportion of damaged cells since uptake of the dye was indicative 
of loss of membrane integrity. 
2.12. MTT Assay  
The MTT reagent was dissolved in PBS (pH=7.4) to prepare a 5 mg/mL stock solution, then 
sterilized through a 0.2 μM filter and stored at 4°C for frequent use, or at -20°C for long term 
storage. 96 well plates were used to carry out cell viability measurements. The final volume 
of test compounds and cells was 100 μL/well. The plates were incubated for 24 h in a 
humidified atmosphere at 37oC and 5% CO2, after which MTT solution (10 μL/well) was 
added, such that the final concentration became 0.45 mg/mL. Thereafter, incubation was 
continued for another 1 to 4 h at 37°C. Finally, 100 μL of solubilisation solution was added to 
each well and the solution absorbances were measured at 570 nm. 
2.13. Statistical analysis  
Results are presented as mean± SD of three separate experiments. GraphPad Prism 7 
software was used to determine the significance of differences between the values. Data 
were analysed by using Analysis of Variance (ANOVA) with Tukey's HSD post hoc test. 
3. Results and discussion 
3.1. Material preparations 
Protein-loaded alginate microparticles with sizes below 100 m, spherical shape and smooth 
morphologies were prepared using an emulsification/internal technique. Thereafter, the 
newly formed particles were coated with high molecular weight (> 310 kDa) chitosan in order 
to reduce the release rate in simulated gastric conditions.. The mean diameter of uncoated 
microspheres was 96 μm but this value increased to 113 μm in the case of the chitosan 
coated microspheres. Optical microscopy observations of microparticles confirmed that their 
spherical shapes and smooth topologies were not affected by chitosan coating. A measure 
of the loading efficiency and the distribution of protein within the microparticles was obtained 
initially using bovine serum albumin–fluorescein isothiocyanate conjugate (BSA-FITC) as a 
model therapeutic protein. As apparent from Figure 2 (right-hand fluorescence microscopy 
images) the protein was clearly present at the surfaces of the microcapsules and in regions 
extending into the interior. Typical protein encapsulation efficiency of the alginate 
microparticles ranged from 75-85%.  
Release studies of bLf were conducted in SGF (pH 1.2, approximate pH of stomach fluid) 
and subsequently in SIF (pH 7.4, chosen to mimic the pH at the initial entry to the colon 
rather than in the distal colon where pH can be 7.8-8.5) to mimic the dynamic conditions of 
physiological gastrointestinal conditions (Figure 3). At pH 1.2 (SGF), a burst release profile 
of protein was observed during the first 30 min of the assay, with uncoated microparticles 
releasing 60-67% of encapsulated bLf protein at pH 1.2 with residual protein gradually 
released at pH 7.4 during the next 90 min. The release of protein was also of a ‘burst profile’ 
at pH 7.4 (SIF) during the first 30 min, then of a slower nature throughout the next 90 min. 
These initial release profiles were likely indicative of protein associated with surface layers of 
the microparticles rather than entrapped within the cores. The final amount of bLf released 
was strongly pH-dependent (Figure 3). This we attribute to pH-dependent differences in the 
electrostatic and hydrogen-bonding interactions of the alginate and chitosan-alginate 
matrices and bLf molecules. In SGF (pH 1.2), the bLf was well below its pI (~7.9) and thus 
highly protonated. Accordingly, exposing bLf loaded alginate microparticles to acidic media 
resulted in neutralization of the negative charge on alginate. This effect led to substantial 
weakening of the electrostatic interaction between bLf and alginate that in turn resulted in 
greater release of encapsulated bLf from the uncoated i.e. alginate-only microspheres at pH 
1.2 compared to the chitosan-coated microspheres. The latter microparticles were expected 
to remain strongly protonated at pH 1.2, thereby retaining bLf in the chitosan-coated regions 
and reducing the burst release at this pH from the coated microspheres, as again apparent 
from Figure 3. Protein leaching from hydrogel beads due to reduced charge interactions has 
been widely reported previously.39 At pH 7.4, the lactoferrin protein was close to neutral 
charge, while the alginate components were more negatively charged, reducing bLf-alginate 
charge-charge repulsion, but the additional factor of microsphere swelling from alginate-
alginate charge-charge repulsion enhanced the release rate of the protein at this higher pH 
value (up to 100% within 2 h).  
As noted above, chitosan-reinforced alginate microparticles showed delayed release of 
proteins at pH 1.2 and the amount of released bLf in SGF after 2 h was reduced to below 
40%. Since chitosan was expected to be positively charged under acidic conditions, the 
reduced release profile may have been due to the charge effects as described above, but 
also a function of the hindered diffusion of bLf caused by the additional polymeric layer, 
which itself was partly charge-related. The release profile at pH 7.4 was similar to that 
observed for uncoated alginate microparticles, with a difference seen in the starting point. 
The overall release of the protein at the same time points was lower for the coated 
microparticles as expected. (Figure 3). These results demonstrated that alginate 
microparticles that were reinforced with chitosan offered more sustained gastrointestinal 
release of protein drugs. However, the incomplete bLf release from the chitosan-coated 
microparticles over the assay period suggested that some of the protein was entrapped in 
tightly charge-cross-linked-regions of the polyelectrolyte complexes between alginate and 
chitosan which did not dissociate even at the higher pH values of the SIF medium. Recent 
studies indicate that this relatively slower release profile can be extended over a time span 
of 20 h.40 
3.2. Cell culture studies 
Epithelial cell culture integrity was monitored by measuring TEER values (Ω.cm2) following 
treatment with the final chitosan-coated alginate microparticles loaded with bLf; decreasing 
values reflect increasing epithelial permeability resulting from membrane or tight-junction 
damage by the protein. The treatment of Caco-2 cells with different forms of encapsulated 
bLf (5 mg/ml) led to increases in TEER values as compared to treatment with toxin A (Figure 
4a) or C. difficile strain 027 bacterial supernatant alone (Figure 5).  These results suggest 
that bLf may have protective effects against C. difficile bacterial supernatant and toxin-
mediated intestinal mucosal damage and impairment of barrier function in intestinal epithelial 
cells.  
The effect of toxin B was more obvious on the metabolic activity of Vero cells. Therefore, an 
MTT assay was used to test cellular mitochondrial dehydrogenase activity, cell growth, and 
survival. There was a significant increase in cell viability, as measured by the MTT cytotoxic 
assay, in Caco-2 monolayers exposed to the higher concentrations (100ng/mL, 1000 ng/mL) 
of toxin A following treatment with chitosan-coated alginate microparticles loaded with 
lactoferrin (Figure 6a). Similar protective effects were seen with Caco-2 monolayers exposed 
to C. difficile bacterial supernatant (Figure 6b). Pre-treatment of Vero cell monolayers with all 
forms of encapsulated bLf followed by exposure to toxin B (Figure 4b) or C. difficile strain 
027 bacterial supernatant for 24 h induced a dose-dependent fall in mitochondrial enzyme 
activity (Figure 6c). 
Phase contrast microscopy studies demonstrated that C. difficile toxin A induced cell 
rounding in the Caco-2 cell lines. Cells within the detached monolayers initially remained 
adherent to each other (Figure 7). Subsequently, floating cells, smaller in size that those 
adherent to each other, appeared in increasing numbers with time. A similar pattern 
emerged for Vero cells exposed to toxin B or bacterial supernatant. Phase contrast 
microscopy images showed that detached Vero cells which had become detached from the 
culture dish seemed to be healthy while adherent to each other (Figure 8). 
4. Conclusions 
There is still limited information regarding the mode of action of lactoferrin and whether 
saturation of the protein with iron or manganese, or its encapsulation, effects its function. 
Currently, most of the in vitro digestion studies indicate that lactoferrin gets completely 
degraded during gastric passage and hence it cannot reach the absorption sites of the 
intestine. 41Therefore, encapsulation could be used to modulate the digestion behaviour of 
lactoferrin and hence achieve sufficient bioavailability through oral administration. The 
objective of this study was to prepare and evaluate colon-specific and pH-triggered alginate 
microparticles to carry and protect free and metal-loaded bLf preparations against enzymatic 
and acidic degradation or loss of bioactivity during gastric passage, to facilitate controlled 
colon release of protein, and to assess subsequently their anti-C. difficile defence properties 
in vitro. In this study, different forms of lactoferrin (iron-depleted; apo-bLf, iron-saturated; 
holo-bLf, and manganese-saturated; Mn-bLf) were encapsulated in chitosan-coated alginate 
microparticles fabricated using the emulsification/internal gelation method. We tested one 
concentration of bLf (5 mg/mL) in line with our previous research which demonstrated that 
this concentration inhibited C. difficile growth and toxin production in a human in vitro gut 
model of C. difficile infection. 35 Moreover, this same concentration was effective in 
significantly reducing the occurrence of antibiotic-associated diarrhoea in long-term care 
patients compared with placebo. 42 
The biological activities of the various encapsulated bLf forms that differed in their metal 
saturation levels were evaluated on intestinal epithelial barrier function following interaction 
with C. difficile purified toxins and bacterial supernatants. The overall results suggest that 
hydrogel microparticles are suitable for capsulation and pH-triggered release of all forms of 
lactoferrin, which may be advantageous for controlled delivery of lactoferrin into the colon. 
Cell culture studies showed that the application of lactoferrin-loaded alginate microparticles 
significantly reduced the cytotoxic effects of purified whole C. difficile toxins A and B as well 
as bacterial supernatant on hIECs, irrespective of metal saturation status. Although our 
findings suggest that encapsulated bLf appears to render intestinal epithelia less susceptible 
to C. difficile toxins and bacterial supernatant, it remains to be determined if encapsulated 
bLf can increase expression of tight junction proteins to enhance epithelial barrier function. 
Whilst recent research has shown that bLf decreases paracellular permeability and 
increases TEER through increased expression of claudin-1, occludin, and zonula occludens-
1 tight junction proteins, 43 others have reported no change in the production of tight junction 
proteins regardless of lactoferrin metal saturation.37 Moreover, it remains unclear if such 
effects observed in the present study can be reproduced in vivo using a murine model of 
CDI. Further laboratory studies will also be required to investigate the immunomodulatory, 
anti-inflammatory and cell-proliferative activities of encapsulated bLf at the mucosal level in 
animal experiments, and if the antimicrobial activity of bLf exerts it beneficial effects on the 
structure and function of the intestinal microbiota. Interestingly, Mn-bLf can deliver 
manganese ions to Lactobacillus strains, thereby enhancing their growth, although it is not 
known if the latter form of bLf can also effect the growth of C. difficile or other bacteria in the 
gut. Moreover, all forms of bLf (apo-, holo, and manganese-saturated) can inhibit secretion 
of pro-inflammatory cytokines from LPS-activated macrophages.37 In addition, 
microencapsulation of L. gasseri and B. bifidum with alginate and chitosan coating can 
significantly improve bacterial survival in simulated gastrointestinal conditions, and allow 
viable cells to reach beneficial levels in the colon.34 
In conclusion, our results are the first to suggest that the chitosan-coated alginate 
microparticles loaded with bLf show protective effects against C. difficile bacteria and toxin-
mediated mucosal damage and impairment of barrier function in hIECs. This may be 
especially advantageous since lactoferrin would be maintained intact under gastric 
conditions, thus reaching the lower gastrointestinal tract where it needs to direct its 
therapeutic effect against this recalcitrant anaerobe and its main virulence factors. 
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Figure Legends 
 
Figure 1 
Schematic shows lactoferrin encapsulation in alginate-based microparticles and release in 
gastric and colonic fluid 
 
Figure 2 
Optical and fluorescent microscopy images of protein-loaded alginate microparticles before 
and after coating with chitosan. Scale bars are 100 µm. 
 
Figure 1 
In vitro release profile of different forms of lactoferrin in simulated gastric fluid (SGF) and in 
simulated intestinal fluid (SIF) for uncoated (blue line) and chitosan-coated (red line) alginate 
microparticles. Results are shown as the means ± standard deviations derived from three 
independent experiments. 
 
Figure 2 
A. The effects of C. difficile toxin A on transepithelial electrical resistance (TEER) of cultured 
Caco-2 enterocytes at 48 h after treatment are reduced by exposure to bovine lactoferrin. 
The TEER is presented as percent change from baseline. Values represent mean ± SE of at 
least 3 tissue culture wells derived from 3 independent experiments. B. Vero cell cytotoxicity 
assay. Vero cells after treatment with bLf and then subjected to different concentrations of 
toxin B, as measured by the MTT cytotoxic assay. Results are shown as the means ± 
standard deviations derived from three independent experiments. **** = p<0.0001; *** = 
p<0.001; ** = p<0.01; * = p<0.05. 
 
Figure 5 
A. TEER% vs. time profiles observed for Caco-2 cell monolayers. B. Effects of different 
forms of metal bound and encapsulated bovine lactoferrin on the TEER (% relative to initial 
value) of polarized Caco-2 cell monolayers in the presence or absence of bacterial 
supernatant samples of the epidemic 027 C. difficile strain at 48 h. Values represent mean ± 
SE of at least 3 tissue culture wells derived from 3 independent experiments. **** = 
p<0.0001 
 
 Figure 6 
Cell viability in Caco-2 monolayers incubated with different form of metal bound and 
encapsulated bovine lactoferrin and then exposed to A. C. difficile toxin A B. bacterial 
supernatant of epidemic 027 C. difficile strain. After culture for 24 h, the percentage of trypan 
blue unstained/viable cells was determined. C. Vero cell cytotoxicity assay. Vero cells after 
treatment with metal bound and alginate encapsulated bovine lactoferrin (Lf-alginate beads) 
and then subjected to bacterial supernatant of epidemic 027 C. difficile strain, as measured 
by the MTT cytotoxic assay. Results are shown as the means ± standard deviations derived 
from three independent experiments. **** = p<0.0001 
 
Figure 7 
Phase contrast photomicrograph of Caco-2 monolayer cells exposed to C. difficile toxin A 
and bacterial supernatant from 027 C. difficile strain. Toxin-exposed monolayer shows cell 
rounding and focal loss of cell-cell contacts. A significant proportion of the monolayer has 
also become detached from the bottom of the culture plate. 
 
Figure 8 
Phase contrast photomicrograph of Vero monolayer cells exposed to C. difficile toxin B and 
bacteria supernatant strain 027 201, PCR ribotype 027. Toxin-exposed monolayer shows 
cell rounding and focal loss of cell-cell contacts. Not evident from the Figure is the fact that a 
significant proportion of the monolayer has also become detached from the bottom of the 
culture plate by this time. 
 
